ANI Pharmaceuticals is building a leading Rare Disease company focused on Serving Patients, Improving Lives

RECENT NEWS

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

2026-07-13

READ MORE >

ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

2026-05-27

READ MORE >

NASDAQ - ANIP

$81.08

-0.99 (-1.21%)

Pricing delayed by 20 minutes
Last updated 2026-07-13 16:00:00